Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
Iterum Therapeutics (Nasdaq: ITRM) has appointed Christine Coyne as Chief Commercial Officer to lead the upcoming U.S. launch of ORLYNVAH™ and future commercialization activities. Coyne brings over 30 years of pharmaceutical industry experience, most recently serving as Chief Commercial Officer at Innoviva.
In her previous roles, Coyne led commercial strategies at several pharmaceutical companies including SCYNEXIS, Paratek Pharmaceuticals, BTG Pharmaceuticals, Auxilium, Endo, and Wyeth/Pfizer. Her expertise in anti-infectives and track record of building commercial infrastructure will be crucial for Iterum's growth plans in addressing infections caused by multi-drug resistant pathogens.
Iterum Therapeutics (Nasdaq: ITRM) ha nominato Christine Coyne Chief Commercial Officer per guidare il prossimo lancio negli Stati Uniti di ORLYNVAH™ e le future attività di commercializzazione. Coyne vanta oltre 30 anni di esperienza nell'industria farmaceutica, avendo ricoperto più recentemente il ruolo di Chief Commercial Officer presso Innoviva.
In precedenza, Coyne ha guidato strategie commerciali in diverse aziende farmaceutiche tra cui SCYNEXIS, Paratek Pharmaceuticals, BTG Pharmaceuticals, Auxilium, Endo e Wyeth/Pfizer. La sua competenza nel settore degli anti-infettivi e la sua esperienza nella costruzione di infrastrutture commerciali saranno fondamentali per i piani di crescita di Iterum nel contrastare infezioni causate da patogeni multi-resistenti.
Iterum Therapeutics (Nasdaq: ITRM) ha nombrado a Christine Coyne como Chief Commercial Officer para liderar el próximo lanzamiento en EE. UU. de ORLYNVAH™ y las futuras actividades de comercialización. Coyne aporta más de 30 años de experiencia en la industria farmacéutica, habiendo desempeñado recientemente el cargo de Chief Commercial Officer en Innoviva.
En sus roles anteriores, Coyne lideró estrategias comerciales en varias compañías farmacéuticas, incluyendo SCYNEXIS, Paratek Pharmaceuticals, BTG Pharmaceuticals, Auxilium, Endo y Wyeth/Pfizer. Su experiencia en antiinfecciosos y su historial en la construcción de infraestructuras comerciales serán clave para los planes de crecimiento de Iterum en el tratamiento de infecciones causadas por patógenos multirresistentes.
Iterum Therapeutics (나스닥: ITRM)는 ORLYNVAH™의 미국 출시 및 향후 상업화 활동을 이끌 신임 최고상업책임자(COO)로 Christine Coyne를 임명했습니다. Coyne는 최근 Innoviva의 최고상업책임자로 재직하는 등 30년 이상의 제약 산업 경력을 보유하고 있습니다.
이전에는 SCYNEXIS, Paratek Pharmaceuticals, BTG Pharmaceuticals, Auxilium, Endo, Wyeth/Pfizer 등 여러 제약사에서 상업 전략을 이끌었습니다. 항감염제 분야의 전문성과 상업 인프라 구축 경험은 다제내성 병원체로 인한 감염 문제를 해결하려는 Iterum의 성장 계획에 중요한 역할을 할 것입니다.
Iterum Therapeutics (Nasdaq : ITRM) a nommé Christine Coyne au poste de Chief Commercial Officer afin de diriger le prochain lancement aux États-Unis d'ORLYNVAH™ ainsi que les futures activités commerciales. Coyne apporte plus de 30 ans d'expérience dans l'industrie pharmaceutique, ayant récemment occupé le poste de Chief Commercial Officer chez Innoviva.
Dans ses fonctions précédentes, Coyne a dirigé les stratégies commerciales de plusieurs entreprises pharmaceutiques, notamment SCYNEXIS, Paratek Pharmaceuticals, BTG Pharmaceuticals, Auxilium, Endo et Wyeth/Pfizer. Son expertise dans les anti-infectieux et son expérience dans la mise en place d'infrastructures commerciales seront essentielles pour les plans de croissance d'Iterum visant à lutter contre les infections causées par des pathogènes multirésistants.
Iterum Therapeutics (Nasdaq: ITRM) hat Christine Coyne zur Chief Commercial Officer ernannt, die den bevorstehenden US-Start von ORLYNVAH™ sowie zukünftige Vermarktungsaktivitäten leiten wird. Coyne bringt über 30 Jahre Erfahrung in der Pharmaindustrie mit und war zuletzt als Chief Commercial Officer bei Innoviva tätig.
In ihren vorherigen Positionen leitete Coyne kommerzielle Strategien bei mehreren Pharmaunternehmen, darunter SCYNEXIS, Paratek Pharmaceuticals, BTG Pharmaceuticals, Auxilium, Endo und Wyeth/Pfizer. Ihre Expertise im Bereich Antiinfektiva und ihre Erfolgsbilanz beim Aufbau kommerzieller Strukturen werden entscheidend für Iterums Wachstumspläne zur Bekämpfung von Infektionen durch multiresistente Krankheitserreger sein.
- Appointment of experienced executive with over 30 years in pharmaceutical industry
- New CCO brings specific expertise in anti-infectives commercialization
- Strategic hire made ahead of important ORLYNVAH™ product launch
- None.
Insights
Iterum's hiring of a seasoned CCO signals imminent ORLYNVAH™ commercialization, strengthening execution potential in the anti-infectives market.
The appointment of Christine Coyne as Chief Commercial Officer represents a strategic milestone in Iterum's transition from development to commercialization. With ORLYNVAH™ approaching its U.S. launch, this timing is particularly significant as it addresses a critical pre-launch need. Coyne brings extensive anti-infective commercialization experience from her roles at Innoviva, SCYNEXIS, and Paratek—all companies with infectious disease portfolios—making her background exceptionally well-aligned for Iterum's needs.
Her track record of building commercial infrastructure from scratch at SCYNEXIS is particularly valuable as Iterum scales its commercial capabilities. The antimicrobial resistance space presents unique commercial challenges, including stewardship considerations that can limit usage, making specialized commercial leadership crucial. Notably, Coyne's experience spans both large pharma environments (Wyeth/Pfizer) and smaller biotech companies, suggesting adaptability to Iterum's growth trajectory.
This appointment signals management's focus on execution ahead of the ORLYNVAH™ launch. While financial terms weren't disclosed, the creation of this position and recruitment of an executive with Coyne's caliber suggests the company is investing substantially in ensuring commercial success. For investors, this represents a positive step toward potential revenue generation in the antibiotic space, which has historically presented commercialization difficulties despite addressing significant medical needs.
DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets.
“We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “Her deep expertise across the commercial spectrum—particularly in anti-infectives—will be instrumental as we aim to accelerate launch readiness for ORLYNVAH™ and scale our capabilities for long-term growth.”
Ms. Coyne brings more than 30 years of commercial and operational experience in the pharmaceutical industry. Most recently, she served as Chief Commercial Officer at Innoviva, where she led the development and execution of go-to-market strategies across the company’s infectious disease and critical care portfolio. Prior to Innoviva, Ms. Coyne held the role of Chief Commercial Officer at SCYNEXIS, where she successfully led the company’s anti-infective portfolio and built its commercial infrastructure from the ground up. Her career also includes senior commercial leadership roles at Paratek Pharmaceuticals, BTG Pharmaceuticals, Auxilium, Endo, and Wyeth/Pfizer.
“I’m honored to join Iterum at such an important moment for both the company and the patients we aim to serve,” said Ms. Coyne. “The upcoming U.S. launch of ORLYNVAH™ represents a significant opportunity to bring innovation to an area with considerable unmet need, and I look forward to leading the team to deliver a successful launch and position Iterum for sustained growth.”
Ms. Coyne holds a Bachelor of Arts from West Chester University and a Master of Business Administration from Eastern University.
About Iterum Therapeutics plc
Iterum is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the FDA and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
About ORLYNVAH™
ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamase (ESBL) or AmpC-type beta-lactamases that confer resistance to third generation cephalosporins.
Cautionary Note Regarding Forward-looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum’s plans, strategies and prospects for its business, including the development, therapeutic and market potential of ORLYNVAH™, and Iterum’s ability to prepare and implement commercialization plans for ORLYNVAH™ and to bring ORLYNVAHTM to market in the U.S. in the next quarter. In some cases, forward-looking statements can be identified by words such as “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “would,” “will,” “future,” “potential” or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum’s control, including Iterum’s ability to raise sufficient capital and successfully prepare and implement commercialization plans for ORLYNVAH™ with its commercialization partner, EVERSANA, including Iterum’s ability to, with the support of EVERSANA, build and maintain a sales force and prepare for a potential commercial launch of ORLYNVAH™, the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if Iterum is unsuccessful at implementing commercialization plans for ORLYNVAH™, the market opportunity for and the potential market acceptance of ORLYNVAH™ for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, Iterum’s ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, commercialization plans and timelines, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum’s expectations regarding how far into the future Iterum’s cash on hand will fund Iterum’s ongoing operations, Iterum’s ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025, and other documents filed with the Securities and Exchange Commission from time to time. Forward-looking statements represent Iterum’s beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
FAQ
Who is the new Chief Commercial Officer of Iterum Therapeutics (ITRM)?
What is Christine Coyne's experience before joining Iterum Therapeutics (ITRM)?
What will be Christine Coyne's main responsibility at Iterum Therapeutics (ITRM)?
What is ORLYNVAH™ by Iterum Therapeutics (ITRM)?
